Back

Updates on enzymatic and structural properties of human glutamine: fructose-6-phosphate amidotransferase 2 (hGFAT2)

Oliveira, I. A.; Allonso, D.; Fernandes, T. V. A.; Lucena, D. M. S.; Ventura, G. T.; Dias, W. B.; Mohana-Borges, R.; Pascutti, P. G.; Todeschini, A. R.

2020-07-14 biochemistry
10.1101/2020.07.13.201285 bioRxiv
Show abstract

Glycoconjugates play a central role in several cellular processes and alteration in their composition is associated to human pathologies. The hexosamine biosynthetic pathway is a route through which cells obtain substrates for cellular glycosylation, and is controlled by the glutamine: fructose-6-phosphate amidotransferase (GFAT). Human isoform 2 GFAT (hGFAT2) has been implicated in diabetes and cancer, however, there is no information about structural and enzymatic properties of this enzyme. Here, we report a successful expression and purification of a catalytically active recombinant hGFAT2 (rhGFAT2) in E. coli cells fused or not to a HisTag at the C-terminal end. Our enzyme kinetics data suggest that hGFAT2 does not follow the ordered bi-bi mechanism, and performs the glucosamine-6-phosphate synthesis much slowly than previously reported for other GFATs. In addition, hGFAT2 is able to isomerase fructose-6-phosphate into glucose-6-phosphate even in presence of equimolar amounts of glutamine, in an unproductive glutamine hydrolysis. Structural analysis of the generated three-dimensional model rhGFAT2, corroborated by circular dichroism data, indicated the presence of a partially structured loop in glutaminase domain, whose sequence is present in eukaryotic enzymes but absent in the E. coli homolog. Molecular dynamics simulations show such loop as the most flexible portion of the protein, which interacts with the protein mainly through the interdomain region, and plays a key role on conformational states of hGFAT2. Altogether, our study provides the first comprehensive set of data on the structure, kinetics and mechanics of hGFAT2, which will certainly contribute for further studies focusing on drug development targeting hGFAT2.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Journal of Biological Chemistry
690 papers in training set
Top 0.1%
27.0%
2
Biochimie
25 papers in training set
Top 0.1%
15.3%
3
The FEBS Journal
93 papers in training set
Top 0.1%
5.6%
4
Biochemical Journal
91 papers in training set
Top 0.3%
4.1%
50% of probability mass above
5
Protein Science
246 papers in training set
Top 1%
4.1%
6
Life Science Alliance
285 papers in training set
Top 1%
3.3%
7
PLOS ONE
5266 papers in training set
Top 42%
2.4%
8
Biochemistry
148 papers in training set
Top 1%
1.9%
9
Scientific Reports
3612 papers in training set
Top 53%
1.8%
10
Biomolecules
100 papers in training set
Top 0.9%
1.8%
11
Current Research in Structural Biology
12 papers in training set
Top 0.1%
1.8%
12
eLife
5828 papers in training set
Top 52%
1.5%
13
mBio
833 papers in training set
Top 8%
1.5%
14
Biochimica et Biophysica Acta (BBA) - General Subjects
18 papers in training set
Top 0.1%
1.4%
15
Bioscience Reports
27 papers in training set
Top 0.8%
1.4%
16
ACS Omega
105 papers in training set
Top 2%
1.1%
17
Archives of Biochemistry and Biophysics
15 papers in training set
Top 0.2%
1.1%
18
FEBS Letters
47 papers in training set
Top 0.3%
1.1%
19
ChemBioChem
55 papers in training set
Top 0.9%
1.1%
20
International Journal of Biological Macromolecules
76 papers in training set
Top 2%
1.0%
21
Communications Biology
993 papers in training set
Top 29%
0.9%
22
Protein Expression and Purification
13 papers in training set
Top 0.1%
0.9%
23
Frontiers in Molecular Biosciences
102 papers in training set
Top 2%
0.9%
24
Biotechnology and Bioengineering
53 papers in training set
Top 1%
0.6%
25
Computational and Structural Biotechnology Journal
242 papers in training set
Top 8%
0.6%
26
Communications Chemistry
48 papers in training set
Top 2%
0.6%
27
Nature Communications
5641 papers in training set
Top 59%
0.6%
28
International Journal of Molecular Sciences
494 papers in training set
Top 17%
0.6%